Diuretic Regimen More Effectively Reduces CV Morbidity vs Telmisartan Combinations in Hypertension With Diabetes
Previous studies on the suitability of diuretics for patients with hypertension and diabetes reveal inconsistencies.
AHA 2018 Meeting Highlights
Combination Therapy May Improve Anticoagulant Activity, Reduce Hypertensive Organ Damage
Coagulant activity was improved with the use of both anticoagulation and antihypertensive therapies in combination.
Gender Differences in ASCVD Care, Quality of Life, and Outcomes
Women with ASCVD are at an increased risk for poor patient experience, lower health-related QOL, and inferior perception of their health compared with men.
Canakinumab May Reduce CV Events in Patients Post-MI With Residual Inflammatory Risk
Canakinumab significantly reduced the total number of CV events in patients with prior MI and residual inflammatory risk.
Antisense Drug Can Safely and Effectively Reduce Elevated Lipoprotein(a)
AKCEA-APO(a)-LRX is efficient and safe in patients with established cardiovascular disease and elevated levels of lipoprotein(a).
CABG Vein Harvesting Techniques Have Similar MACE Risks
In patients undergoing coronary artery bypass grafting, no significant difference was found between endoscopic and open vein graft harvesting in terms of MACE risk.
Primary Prevention With Marine Omega-3 Fatty Acids Did Not Modify MACE Risk
Supplementation with omega-3 fatty acids did not result in a lower MACE incidence compared with placebo.
Chronic CCB Therapy Linked to Improved Outcomes After CABG Utilizing the Radial Artery
Mario F.L. Gaudino, MD, and colleagues evaluated whether calcium-channel blocker therapy influences clinical and angiographic outcomes of radial artery grafts used for coronary bypass surgery.
Dapagliflozin Lowers Heart Failure Hospitalization Rates in High-Risk Patients With Diabetes
Dapagliflozin was not associated with either a higher or lower rate of MACE compared with placebo in patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease.
Sacubitril-Valsartan Superior to Enalapril for Reducing NT-proBNP in HFrEF
A sacubitril-valsartan therapy regimen was associated with greater reductions in NT-proBNP concentrations in patients with HFrEF compared with enalapril.
Want to read more?
Please login or register first to view this content.
Next post in AHA 2018 Meeting Highlights
